# Insulin glargine U-300 Max

NDC: 0955-2900
Generic name: insulin glargine
Labeler / Manufacturer: Sanofi-Aventis U.S. LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: SUBCUTANEOUS
Marketing started: 20230401

FDA application: BLA206538

## Active ingredients

- INSULIN GLARGINE: 300 [iU]/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0955-2900"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0955-2900
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=99ea856d-9562-443a-9422-1006a3cff2f4